logo
logo

Unlearn.AI Announces Series A Extension with New Investment from Epic Ventures, Alumni Ventures Group, and Global Pharma Company Eisai

Nov 05, 2020•almost 5 years ago

Round Type

series a

San FranciscoBiotechnologyHealth Care

Description

Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that Eisai, a leading global research and development-based pharmaceutical company, has joined the company’s world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group. In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures. The extension brings the Series A total to $15 million.

Company Information

Company

Unlearn

Location

San Francisco, California, United States

About

Unlearn partners with pharma and biotech companies to design and optimize clinical trials using AI-powered digital twins. By forecasting patients’ clinical outcomes, Unlearn helps sponsors refine trial design, shorten timelines, and increase the chance of detecting treatment effects in less time. With a science-first approach and deep regulatory engagement—including EMA qualification and FDA endorsement—Unlearn is transforming clinical development to be faster, smarter, and more reliable.

Related People